WO2004089415A3 - Therapie combinatoire utilisant un inhibiteur de 11$g(b)-hydroxysteroide deshydrogenase de type 1 et agoniste du recepteur de glucocorticoides pour minimiser les effets secondaires associes a la therapie a base d'agoniste du recepteur de glucocorticoides - Google Patents

Therapie combinatoire utilisant un inhibiteur de 11$g(b)-hydroxysteroide deshydrogenase de type 1 et agoniste du recepteur de glucocorticoides pour minimiser les effets secondaires associes a la therapie a base d'agoniste du recepteur de glucocorticoides Download PDF

Info

Publication number
WO2004089415A3
WO2004089415A3 PCT/DK2004/000248 DK2004000248W WO2004089415A3 WO 2004089415 A3 WO2004089415 A3 WO 2004089415A3 DK 2004000248 W DK2004000248 W DK 2004000248W WO 2004089415 A3 WO2004089415 A3 WO 2004089415A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor agonist
inhibitor
hydroxysteroid dehydrogenase
glucocorticoid receptor
combinations
Prior art date
Application number
PCT/DK2004/000248
Other languages
English (en)
Other versions
WO2004089415A2 (fr
Inventor
Gita Camilla Tejlgaard Kampen
Henrik Sune Andersen
Original Assignee
Novo Nordisk As
Gita Camilla Tejlgaard Kampen
Henrik Sune Andersen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Gita Camilla Tejlgaard Kampen, Henrik Sune Andersen filed Critical Novo Nordisk As
Priority to EP04725890A priority Critical patent/EP1615667A2/fr
Priority to JP2006504351A priority patent/JP2006522744A/ja
Publication of WO2004089415A2 publication Critical patent/WO2004089415A2/fr
Publication of WO2004089415A3 publication Critical patent/WO2004089415A3/fr
Priority to US11/246,814 priority patent/US20060094699A1/en
Priority to US12/491,659 priority patent/US20090264412A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une thérapie combinatoire comprenant l'administration d'un inhibiteur de 11β-hydroxystéroïde déshydrogénase de type 1 et d'un agoniste du récepteur de glucocorticoïdes destinée au traitement de certaines formes de cancer, de maladies et de troubles dont l'inflammation est une composante, et permettant de minimiser les effets secondaires associés à la thérapie à base d'agoniste du récepteur de glucocorticoïdes.
PCT/DK2004/000248 2003-04-11 2004-04-06 Therapie combinatoire utilisant un inhibiteur de 11$g(b)-hydroxysteroide deshydrogenase de type 1 et agoniste du recepteur de glucocorticoides pour minimiser les effets secondaires associes a la therapie a base d'agoniste du recepteur de glucocorticoides WO2004089415A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP04725890A EP1615667A2 (fr) 2003-04-11 2004-04-06 Therapie combinatoire utilisant un inhibiteur de 11beta-hydroxysteroide deshydrogenase de type 1 et agoniste du recepteur de glucocorticoides
JP2006504351A JP2006522744A (ja) 2003-04-11 2004-04-06 グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
US11/246,814 US20060094699A1 (en) 2003-04-11 2005-10-07 Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
US12/491,659 US20090264412A1 (en) 2003-04-11 2009-06-25 Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy

Applications Claiming Priority (58)

Application Number Priority Date Filing Date Title
DKPA200300998 2003-02-07
DKPA200300571 2003-04-11
DKPA200300571 2003-04-11
DKPA200300566 2003-04-11
DKPA200300566 2003-04-11
DKPA200300565 2003-04-11
DKPA200300568 2003-04-11
DKPA200300568 2003-04-11
DKPA200300570 2003-04-11
DKPA200300570 2003-04-11
DKPA200300565 2003-04-11
DKPA200300569 2003-04-11
DKPA200300569 2003-04-11
US46780003P 2003-05-02 2003-05-02
US46745303P 2003-05-02 2003-05-02
US46736303P 2003-05-02 2003-05-02
US46728403P 2003-05-02 2003-05-02
US46736203P 2003-05-02 2003-05-02
US46744303P 2003-05-02 2003-05-02
US60/467,443 2003-05-02
US60/467,800 2003-05-02
US60/467,362 2003-05-02
US60/467,453 2003-05-02
US60/467,284 2003-05-02
US60/467,363 2003-05-02
DKPA20030778 2003-05-22
DKPA200300776 2003-05-22
DKPA200300776 2003-05-22
DKPA200300778 2003-05-22
US47515703P 2003-06-02 2003-06-02
US47519503P 2003-06-02 2003-06-02
US60/475,157 2003-06-02
US60/475,195 2003-06-02
DKPA200300972 2003-06-27
DKPA200300972 2003-06-27
DKPA200300989 2003-06-30
DKPA200300989 2003-06-30
DKPA200300990 2003-06-30
DKPA200300988 2003-06-30
DKPA200300990 2003-06-30
DKPA200300988 2003-06-30
DKPA200300998 2003-07-02
US48609803P 2003-07-10 2003-07-10
US48609503P 2003-07-10 2003-07-10
US48607803P 2003-07-10 2003-07-10
US48609403P 2003-07-10 2003-07-10
US48609703P 2003-07-10 2003-07-10
US60/486,078 2003-07-10
US60/486,095 2003-07-10
US60/486,097 2003-07-10
US60/486,094 2003-07-10
US60/486,098 2003-07-10
DKPA200301910 2003-12-22
DKPA200301910 2003-12-22
DKPA200400009 2004-01-06
DKPA200400009 2004-01-06
US53709904P 2004-01-16 2004-01-16
US60/537,099 2004-01-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/246,814 Continuation US20060094699A1 (en) 2003-04-11 2005-10-07 Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy

Publications (2)

Publication Number Publication Date
WO2004089415A2 WO2004089415A2 (fr) 2004-10-21
WO2004089415A3 true WO2004089415A3 (fr) 2005-03-10

Family

ID=33163367

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000248 WO2004089415A2 (fr) 2003-04-11 2004-04-06 Therapie combinatoire utilisant un inhibiteur de 11$g(b)-hydroxysteroide deshydrogenase de type 1 et agoniste du recepteur de glucocorticoides pour minimiser les effets secondaires associes a la therapie a base d'agoniste du recepteur de glucocorticoides

Country Status (3)

Country Link
EP (1) EP1615667A2 (fr)
JP (1) JP2006522744A (fr)
WO (1) WO2004089415A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US8927549B2 (en) 2008-11-21 2015-01-06 High Point Pharmaceuticals, Llc Adamantyl benzamide derivatives
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535889A (en) 2002-03-26 2006-03-31 Boehringer Ingelheim Pharma Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
ATE482747T1 (de) * 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
SE0301232D0 (sv) * 2003-04-25 2003-04-25 Astrazeneca Ab Novel use
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
WO2005090320A2 (fr) * 2004-03-12 2005-09-29 Wyeth Derives de triazole et leur methode d'utilisation pour traiter les infections par le vih
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
JP5014983B2 (ja) 2004-05-07 2012-08-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ １１−ベータヒドロキシステロイドデヒドロゲナーゼ阻害剤としてのピロリジン−２−オン及びピペリジン−２−オン誘導体
US20060063930A1 (en) * 2004-08-20 2006-03-23 Agoston Gregory E Compositions and methods comprising proteinase activated receptor antagonists
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
JP5208505B2 (ja) * 2004-08-30 2013-06-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ １１−ベータヒドロキシステロイドデヒドロゲナーゼ阻害剤としてのｎ−２アダマンタニル−２−フェノキシ−アセトアミド誘導体
JP5137574B2 (ja) 2004-08-30 2013-02-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ １１−ベータヒドロキシステロイドヒドロゲナーゼ阻害剤としての三環式ラクタム誘導体
WO2006046915A1 (fr) * 2004-10-29 2006-05-04 Astrazeneca Ab Utilisation de derives insatures de quinoline ou de naphtalene comme medicaments
EP1817295B1 (fr) 2004-11-18 2012-11-07 Synta Pharmaceuticals Corp. Composes triazole modulant l'activite de hsp90
PE20060776A1 (es) 2004-12-27 2006-09-26 Boehringer Ingelheim Pharma Mimeticos de glucocorticoides, metodos para prepararlos y composiciones farmaceuticas
JP4880671B2 (ja) 2005-04-05 2012-02-22 エフ．ホフマン−ラ ロシュ アーゲー １Ｈ−ピラゾール４−カルボキシルアミドその製造方法および１１β−ヒドロキシステロイドデヒドロゲナーゼとしてのその使用
KR100970294B1 (ko) * 2005-06-08 2010-07-15 니뽄 다바코 산교 가부시키가이샤 복소환 화합물
JP5368789B2 (ja) * 2005-06-17 2013-12-18 アポジー・バイオテクノロジー・コーポレイション スフィンゴシンキナーゼ阻害剤
AU2006338265B2 (en) 2005-08-18 2011-04-14 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US7622492B2 (en) 2005-08-31 2009-11-24 Hoffmann-La Roche Inc. Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
TW200734313A (en) * 2006-01-17 2007-09-16 Astrazeneca Ab Piperazines and piperidines as mGluR5 potentiators
AU2007207055B2 (en) 2006-01-18 2011-06-02 F. Hoffmann-La Roche Ag Thiazoles as 11 beta-HSD1 inhibitors
KR20110007258A (ko) 2006-03-22 2011-01-21 에프. 호프만-라 로슈 아게 11-베타-ｈｓｄ-1로서의 피라졸
EP1998760A2 (fr) * 2006-03-30 2008-12-10 James E. Summerton Compositions outils oncologiques et procédés d'utilisation pour détecter et traiter des tumeurs
US8034834B2 (en) 2006-05-25 2011-10-11 Synta Pharmaceuticals Corp. Method for treating proliferative disorders with HSP90 inhibitors
CA2653332A1 (fr) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Composes de triazole qui modulent l'activite de la hsp90
US8115005B2 (en) 2006-08-04 2012-02-14 Decode Genetics Ehf. Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation
BRPI0714622A2 (pt) 2006-08-04 2013-04-30 Merz Pharma Gmbh & Co Kgaa pirazolopirimidinas substituÍdas, processo para sua preparaÇço e seu uso como medicamento
KR20090040478A (ko) 2006-08-24 2009-04-24 노파르티스 아게 ２-(피라진-２-일)-티아졸 및 ２-(１Ｈ-피라졸-３-일)-티아졸 유도체, 및 대사, 심혈관 및 기타 장애의 치료를 위한 스테아로일-ＣｏＡ 데새투라제(ＳＣＤ) 억제제로서의 관련 화합물
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2008029168A2 (fr) * 2006-09-08 2008-03-13 Summit Corporation Plc Traitement de la dystrophie musculaire de duchenne
CN101516877B (zh) 2006-09-22 2013-09-11 诺瓦提斯公司 杂环有机化合物
RU2470040C2 (ru) * 2006-10-17 2012-12-20 Ратджерс, Те Стейт Юниверсити Оф Нью Джерси N-замещенные мономеры и полимеры
JP2010512331A (ja) 2006-12-06 2010-04-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルココルチコイド模倣薬、それらの製造方法、医薬組成物、及びこれらの使用
AU2007336238A1 (en) 2006-12-20 2008-06-26 Novartis Ag 2-substituted 5-membered heterocycles as SCD inhibitors
US20110003852A1 (en) 2007-02-23 2011-01-06 Soren Ebdrup N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
JP2010519240A (ja) 2007-02-23 2010-06-03 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼの阻害剤としての、ｎ−アダマンチルベンズアミド
BRPI0806847A2 (pt) 2007-02-23 2014-04-29 High Point Pharmaceuticals Llc N-adamantil benzamidas como inibidores de 11-beta-hidroxiesteróide desidrogenase
AU2008233088B2 (en) * 2007-03-30 2013-09-26 Amgen Inc. Calcimimetic compounds for use in the treatment of bowel disorders
CA2682567A1 (fr) * 2007-03-30 2008-10-09 James E. Summerton Molecules non-peptidiques pour la detection et le traitement des tumeurs
WO2008134036A1 (fr) * 2007-04-27 2008-11-06 Panacos Pharmaceuticals, Inc. DÉRIVÉS D'AMIDE PYRIMIDE ARYLMETHYL PYRAZOLO[1,5-α ] À SUBSTITUTION ALPHA
CN101743226B (zh) 2007-07-17 2012-10-10 霍夫曼-拉罗奇有限公司 11β-羟基类固醇脱氢酶抑制剂
WO2009015067A2 (fr) * 2007-07-25 2009-01-29 Boehringer Ingelheim International Gmbh Mimétiques de glucocorticoïdes, leurs procédés de production, compositions pharmaceutiques et utilisations associées
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
FR2929851B1 (fr) * 2008-04-09 2012-11-30 Centre Nat Rech Scient Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
CA2726449A1 (fr) 2008-06-06 2009-12-10 Boehringer Ingelheim International Gmbh Mimetiques de glucocorticoides, leurs procedes de fabrication, des compositions pharmaceutiques et leurs utilisations
PE20110843A1 (es) 2008-09-22 2011-12-08 Cayman Chem Co Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica
CA2952692C (fr) 2008-09-22 2020-04-28 Array Biopharma Inc. Composes imidazo[1,2b]pyridazine substitues
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
HUE037716T2 (hu) 2008-10-22 2018-09-28 Array Biopharma Inc Szubsztituált pirazolo[l,5-a]pirimidin vegyületek mint TRK kináz inhibitorok
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2011047432A1 (fr) * 2009-10-22 2011-04-28 Fibrotech Therapeutics Pty Ltd Analogues à cycles condensés d'agents anti-fibrotiques
WO2011106273A1 (fr) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Nouveaux dérivés benzimidazole cycliques utiles comme agents antidiabétiques
EP2560640A1 (fr) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Thérapie anticancéreuse à l'aide d'une combinaison d'un composé inhibiteur de hsp90 et d'un inhibiteur d'egfr
MY191934A (en) 2010-05-20 2022-07-19 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
AU2011202542A1 (en) * 2010-07-14 2012-02-02 Indian Institute Of Science Benzothiophene carboxamide compounds, composition and applications thereof
FR2962649A1 (fr) 2010-07-19 2012-01-20 Conservatoire Nat Arts Et Metiers Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
US8513430B2 (en) 2010-07-27 2013-08-20 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
US8796258B2 (en) 2011-02-25 2014-08-05 Merck Sharp & Dohme Corp. Cyclic azabenzimidazole derivatives useful as anti-diabetic agents
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
US9439899B2 (en) 2011-11-02 2016-09-13 Synta Pharmaceuticals Corp. Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
CA2902333C (fr) 2013-03-13 2021-06-08 Unilever Plc Compositions cosmetiques contenant des amides tricyclodecanes
EP2968094B1 (fr) 2013-03-13 2018-05-30 Unilever PLC Composition photoprotectrice contenant les amides de tricyclododecane
ES2623061T3 (es) 2013-03-13 2017-07-10 Unilever N.V. Liberación prolongada de determinados componentes de fragancias de composiciones para el cuidado personal
EP2970119B1 (fr) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
CN103420931B (zh) * 2013-05-02 2015-07-08 范国煌 调节巨噬细胞极化并抗糖尿病的五环化合物及其应用
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
CN105829284B (zh) 2013-12-09 2019-01-22 荷兰联合利华有限公司 制备金刚烷甲酰胺类化合物的方法
US9381171B2 (en) 2013-12-19 2016-07-05 Samsung Electronics Co., Ltd. Composition including dapsone for preventing or treating side effect of steroid in subject and use of the composition
JP2017516850A (ja) 2014-05-23 2017-06-22 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｊａｋ阻害剤である５−クロロ−２−ジフルオロメトキシフェニルピラゾロピリミジン化合物
KR102529578B1 (ko) 2014-08-29 2023-05-09 (주)아모레퍼시픽 신규 아다만탄 유도체 화합물
WO2016073738A2 (fr) 2014-11-05 2016-05-12 Flexus Biosciences, Inc. Agents immunorégulateurs
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
SI3699181T1 (sl) 2014-11-16 2023-06-30 Array Biopharma, Inc. Kristalinična oblika(s)-n-(5-((r)-2-(2,5-difluorofenil)- pirolidin-1-il)-pirazolo(1,5-a)pirimidin-3-il)-3-hidroksipirolidin-1 -karboksamid hidrogen sulfata
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
TN2018000335A1 (en) 2016-04-04 2020-01-16 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
ES2952056T3 (es) 2016-05-18 2023-10-26 Loxo Oncology Inc Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CN109803951B (zh) * 2016-11-08 2020-12-04 正大天晴药业集团股份有限公司 作为cccDNA抑制剂的磺酰胺类化合物
EP3548035A4 (fr) 2016-11-30 2020-07-22 Case Western Reserve University Combinaisons d'inhibiteurs de 15-pgdh avec des corcostéroïdes et/ou des inhibiteurs du tnf et leurs utilisations
EP3551176A4 (fr) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Composés hétérocycliques antidiabétiques
EP3558298A4 (fr) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. Composés de spirochromane antidiabétiques
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US11426420B2 (en) 2017-04-07 2022-08-30 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating coronary disorders
RU2769696C2 (ru) 2017-05-22 2022-04-05 Ф. Хоффманн-Ля Рош Аг Терапевтические соединения и композиции и способы их применения
WO2020142559A1 (fr) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibiteurs de l'interaction ménine-mll
CN114040760A (zh) 2018-12-31 2022-02-11 拜欧米富士恩公司 Menin-mll相互作用的不可逆抑制剂
US20220288033A1 (en) * 2019-09-04 2022-09-15 Agency For Science, Technology And Research Heterocyclic compounds as modulators of beta-catenin / tcf4 interaction
JP2022554392A (ja) * 2019-11-05 2022-12-28 デルミラ インコーポレイテッド ＭｒｇｐｒＸ２アンタゴニストおよびその使用
CA3229150A1 (fr) 2021-08-20 2023-02-23 Biomea Fusion, Inc. Formes cristallines de n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidine-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propene-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, un inhibiteur irreversible de menine-mll pour le traitement du cance

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072084A2 (fr) * 2001-03-08 2002-09-19 Sterix Limited Utilisation
WO2002076435A2 (fr) * 2001-03-23 2002-10-03 The University Of Edinburgh Modulation d'un profile lipidique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615697A2 (fr) * 2003-04-11 2006-01-18 Novo Nordisk A/S Utilisation pharmaceutique de pyrazolo 1,5-a]pyrimidines substituees

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072084A2 (fr) * 2001-03-08 2002-09-19 Sterix Limited Utilisation
WO2002076435A2 (fr) * 2001-03-23 2002-10-03 The University Of Edinburgh Modulation d'un profile lipidique

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927549B2 (en) 2008-11-21 2015-01-06 High Point Pharmaceuticals, Llc Adamantyl benzamide derivatives
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK

Also Published As

Publication number Publication date
EP1615667A2 (fr) 2006-01-18
WO2004089415A2 (fr) 2004-10-21
JP2006522744A (ja) 2006-10-05

Similar Documents

Publication Publication Date Title
WO2004089415A3 (fr) Therapie combinatoire utilisant un inhibiteur de 11$g(b)-hydroxysteroide deshydrogenase de type 1 et agoniste du recepteur de glucocorticoides pour minimiser les effets secondaires associes a la therapie a base d'agoniste du recepteur de glucocorticoides
TW200507830A (en) Bronchodilating β -agonist compositions and methods
AU2003297684A1 (en) Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
WO2002072031A3 (fr) Composes de tetracycline substitue utilises en tant qu'antifongiques synergiques
WO2006047516A3 (fr) Composes et compositions servant d'inhibiteurs d'activite de recepteur cannabinoide de type 1
WO2004006859A3 (fr) Composes de platine
WO2007061661A3 (fr) Inhibiteurs de la 11-beta-hydroxy steroide deshydrogenase de type 1
WO2008019357A3 (fr) Composés d'indole
HK1149764A1 (fr)
WO2004093814A3 (fr) Compositions a base d'un inhibiteur selectif de la cyclooxygenase-2 et d'un bloqueur du canal d'ions sodium pour le traitement de la douleur, de l'inflammation ou de troubles medies par l'inflammation
WO2005000213A3 (fr) Methode permettant de traiter des maladies a l'aide d'agent d'inhibition hsp90 combines a des inhibiteurs d'enzymes
WO2005115547A3 (fr) Compositions destinees a soigner les troubles du sommeil
WO2006088814A3 (fr) Forme posologique et procede de liberation soutenue d'un compose pyrazine substitue
WO2003088748A8 (fr) Utilisation d'heme-oxygenase-1 et produits de degradation d'heme
WO2003072048A3 (fr) Soulagement des symptomes des troubles gastro-intestinaux
WO2005000214A3 (fr) Methode permettant de traiter des maladies a l'aide d'agents d'inhibition hsp90 combines a des antibiotiques
WO2004103283A3 (fr) Compositions comprenant un inhibiteur selectif de cyclooxygenase-2 et un stimulant de systeme nerveux central pour le traitement d'une lesion du systeme nerveux central
AU2003298913A1 (en) Treatment of inflammatory disorders with 2,3-benzodiazepines
EP1940377A4 (fr) Compositions analgesiques topiques de n,2,3-trimethyl-2-isopropylbutamide et procedes pour les utiliser
WO2008027796A3 (fr) Compositions et methodes de traitement ou de prevention du glaucome ou de son evolution
WO2002072021A3 (fr) Agents et procedes pour la prevention de l'apparition initiale ou de la recurrence des cancers existants
WO2005013911A3 (fr) Usages protecteurs et therapeutiques de tocotrienols
AU2003285281A1 (en) Topical application of curcumin for the treatment of peripheral neuropathy
WO2008033655A3 (fr) Compositions et procédés de traitement, de contrôle, de réduction, d'amélioration ou de prévention des allergies
WO2004016151A3 (fr) Modulateurs de la prolifération des cellules du muscle lisse dérivés de pthrp

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004725890

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11246814

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006504351

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004725890

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11246814

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2004725890

Country of ref document: EP